Hepatobiliary Neoplasm Clinical Trial
— LiVeRTrainerOfficial title:
Effectiveness of an Immersive Virtual Reality Environment on Curricular Training for Complex Cognitive Skills in Liver Surgery: A Multicentric Crossover Randomized Trial
Verified date | July 2021 |
Source | University Hospital, Ghent |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Investigators hypothesize that a virtual reality (VR) environment enhances general surgery residents' performance compared to Desktop Interface (DI)-based visualization of 3D models in decision making for patients with liver tumors. To determine this, a proficiency-based stepwise training curriculum for preoperative planning has been developed using both modalities. The overall objective of the curriculum is that by the end of the training program, residents would be able to formulate a treatment plan for patients with liver tumors.
Status | Completed |
Enrollment | 50 |
Est. completion date | June 15, 2021 |
Est. primary completion date | April 19, 2021 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: • General surgery residents irrespective of their postgraduate year Exclusion Criteria: - No inform consent - Residents of other specialties |
Country | Name | City | State |
---|---|---|---|
Belgium | Ghent University Hospital | Ghent | |
Italy | Federico II University | Naples |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Ghent |
Belgium, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Residents' decision-making accuracy | Residents' decision-making accuracy when reviewing patient data and 3D liver models using DI or VR, measured by comparing their performance to experts' opinions.
The measurement tool will be a questionnaire consisting of ten questions, rate of correct answers will be recorded (e.g. 8/10 correct answers) and higher scores mean a better outcome. Minimum score=0; Maximum score=10. |
Immediately after completing the educational intervention | |
Secondary | Cognitive knowledge retention | Retention of knowledge assessed by validated multiple choice questions. Questionnaire consisted of 15 questions will be used, rate of correct answers will be recorded (e.g. 8/15 correct answers), and higher scores mean a better outcome.
Minimum score=0; Maximum score=15. |
Baseline and immediately after completing the educational intervention | |
Secondary | Residents' scores in recognizing intrahepatic structures and liver segments | Assessed by recognizing intrahepatic structures and 8 liver segments. Questionnaire consisted of 22 questions will be used, rate of correct answers will be recorded (e.g. 8/22 correct answers), and higher scores mean a better outcome.
Minimum score=0; Maximum score=22. |
Immediately after completing the educational intervention | |
Secondary | Time needed to devise a surgical plan using the DI or VR platform | Assessed by total time needed to make decision for 10 patient cases in minutes | Immediately after completing the educational intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01020812 -
Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Completed |
NCT06049836 -
Holographic Augmented Reality Versus Screen Visualisation of 3D Rendering Models for the Pre-operative Evaluation and Planning of Liver Resections
|
N/A | |
Completed |
NCT01135849 -
B-Receptor Signaling in Cardiomyopathy
|
N/A | |
Recruiting |
NCT04010071 -
Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors
|
Phase 2 | |
Recruiting |
NCT04709445 -
Perfusion Rate Assessment by Near-infrared Fluorescence in Gastrointestinal Anastomoses
|
N/A | |
Terminated |
NCT01151761 -
PII of SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation
|
Phase 2 | |
Active, not recruiting |
NCT04501913 -
Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes
|
||
Withdrawn |
NCT03818997 -
Combination of Targeted and Immunotherapy for Advanced Biliary Tract and Esophagogastric Gastric Cancer
|
Phase 2 | |
Completed |
NCT04642664 -
Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
|
Phase 2 | |
Not yet recruiting |
NCT03760289 -
DKN-01/Atezolizumab as Second Line Treatment of biliarY Tract Cancer and in combiNAtion or Not With Paclitaxel as Second Line treatMent of esophagogastrIC Cancer
|
Phase 2 | |
Terminated |
NCT00767234 -
Permission to Collect Blood Over Time for Research
|
N/A |